Neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy yield similar overall survival in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/folfirinox-vs-crt-pancreatic-cancer-one-better-2025a1000p19?src=rss
Author :
Publish date : 2025-09-19 17:55:00
Copyright for syndicated content belongs to the linked Source.
